Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis

Journal of Oncology

Volumn , Issue , 2011, Pages

  Lu, Bo ^b   Morrison, Ryan ^a   Schleicher, Stephen M ^b   Sun, Yunguang ^b   Niermann, Kenneth J ^b   Kim, Sungjune ^b   Spratt, Daniel E ^b   Chung, Christine H ^b  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 833923; ETODOLAC; GDC 0449; LDE 225; MK 0752; PARTHENOLIDE; PF 03084014; PF 04449913; RESVERATROL; RO 4929097; SALINOSPORAMIDE A; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LYMPHATIC LEUKEMIA; MEDULLOBLASTOMA; PANCREAS CANCER; PROTEIN TARGETING; RECURRENCE RISK; REVIEW; SOLID TUMOR; THERAPY RESISTANCE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UNITED STATES;

EID: 78349234668     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2011/941876     Document Type: Review

References (121)

1. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M. A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort The Lancet 2010 375 9712 377 384
2. Spielmann M., Roch H., Delozier T., Canon J. -L., Romieu G., Bourgeois H., Extra J. -M., Serin D., Kerbrat P., Machiels J. -P., Lortholary A., Orfeuvre H., Campone M., Hardy-Bessard A. -C., Coudert B., Maerevoet M., Piot G., Kramar A., Martin A. -L., Penault-Llorca F., Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial Journal of Clinical Oncology 2009 27 36 6129 6134
3. Fleming G. F., Sill M. W., Darcy K. M., McMeekin D. S., Thigpen J. T., Adler L. M., Berek J. S., Chapman J. A., DiSilvestro P. A., Horowitz I. R., Fiorica J. V., Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecologic Oncology 2010 116 1 15 20
4. Kopetz S., Hoff P. M., Morris J. S., Wolff R. A., Eng C., Glover K. Y., Adinin R., Overman M. J., Valero V., Wen S., Lieu C., Yan S., Tran H. T., Ellis L. M., Abbruzzese J. L., Heymach J. V., Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance Journal of Clinical Oncology 2010 28 3 453 459
5. Penson R. T., Dizon D. S., Cannistra S. A., Roche M. R., Krasner C. N., Berlin S. T., Horowitz N. S., DiSilvestro P. A., Matulonis U. A., Lee H., King M. A., Campos S. M., Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mllerian tumors Journal of Clinical Oncology 2010 28 1 154 159
6. Kies M. S., Holsinger F. C., Lee J. J., William Jr. W. N., Glisson B. S., Lin H. Y., Lewin J. S., Ginsberg L. E., Gillaspy K. A., Massarelli E., Byers L., Lippman S. M., Hong W. K., El-Naggar A. K., Garden A. S., Papadimitrakopoulou V., Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial Journal of Clinical Oncology 2010 28 1 8 14
7. de Lima M., Champlin R. E., Thall P. F., Wang X., Martin T. G. III, Cook J. D., McCormick G., Qazilbash M., Kebriaei P., Couriel D., Shpall E. J., Khouri I., Anderlini P., Hosing C., Chan K. W., Andersson B. S., Patah P. A., Caldera Z., Jabbour E., Giralt S., Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome Leukemia 2008 22 2 258 264
8. Candoni A., Martinelli G., Toffoletti E., Chiarvesio A., Tiribelli M., Malagola M., Piccaluga P. P., Michelutti A., Simeone E., Damiani D., Russo D., Fanin R., Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years Leukemia Research 2008 32 12 1800 1808
9. Chang J. E., Voorhees P. M., Kolesar J. M., Ahuja H. G., Sanchez F. A., Rodriguez G. A., Kim K., Wemdli J., Bailey H. H., Kahl B. S., Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study Hematological Oncology 2009 27 1 11 16
10. Bhojwani D., Moskowitz N., Raetz E. A., Carroll W. L., Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia Pediatric Drugs 2007 9 3 149 156
11. Thirukkumaran C., Morris D. G., Oncolytic viral therapy using reovirus Methods in Molecular Biology 2009 542 607 634
12. Kort E. J., Paneth N., Vande Woude G. F., The decline in U.S. cancer mortality in people born since 1925 Cancer Research 2009 69 16 6500 6505
13. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. J., Cancer statistics, 2008 CA: Cancer Journal for Clinicians 2008 58 2 71 96
14. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M. A., Dick J. E., A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 1994 367 6464 645 648
15. Eyler C. E., Rich J. N., Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis Journal of Clinical Oncology 2008 26 17 2839 2845
16. Dalerba P., Cho R. W., Clarke M. F., Cancer stem cells: models and concepts Annual Review of Medicine 2007 58 267 284 (Pubitemid 46706514)
17. Barker N., Ridgway R. A., Van Es J. H., Van De Wetering M., Begthel H., Van Den Born M., Danenberg E., Clarke A. R., Sansom O. J., Clevers H., Crypt stem cells as the cells-of-origin of intestinal cancer Nature 2009 457 7229 608 611
18. Zhu L., Gibson P., Currle D. S., Tong Y., Richardson R. J., Bayazitov I. T., Poppleton H., Zakharenko S., Ellison D. W., Gilbertson R. J., Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation Nature 2009 457 7229 603 607
19. Prez-Caro M., Cobaleda C., Gonzlez-Herrero I., Vicente-Dueas C., Bermejo-Rodrguez C., Snchez-Beato M., Orfao A., Pintado B., Flores T., Snchez-Martn M., Jimnez R., Piris M. A., Snchez-Garca I., Cancer induction by restriction of oncogene expression to the stem cell compartment EMBO Journal 2009 28 1 8 20
20. Rosen J. M., Jordan C. T., The increasing complexity of the cancer stem cell paradigm Science 2009 324 5935 1670 1673
21. Kelly P. N., Dakic A., Adams J. M., Nutt S. L., Strasser A., Tumor growth need not be driven by rare cancer stem cells Science 2007 317 5836 337
22. Bonnet D., Dick J. E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell Nature Medicine 1997 3 7 730 737
23. Hemmati H. D., Nakano I., Lazareff J. A., Masterman-Smith M., Geschwind D. H., Bronner-Fraser M., Kornblum H. I., Cancerous stem cells can arise from pediatric brain tumors Proceedings of the National Academy of Sciences of the United States of America 2003 100 25 15178 15183
24. Al-Hajj M., Wicha M. S., Benito-Hernandez A., Morrison S. J., Clarke M. F., Prospective identification of tumorigenic breast cancer cells Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 3983 3988 (Pubitemid 36418143)
25. Ricci-Vitiani L., Lombardi D. G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R., Identification and expansion of human colon-cancer-initiating cells Nature 2007 445 7123 111 115
26. Prince M. E., Sivanandan R., Kaczorowski A., Wolf G. T., Kaplan M. J., Dalerba P., Weissman I. L., Clarke M. F., Ailles L. E., Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma Proceedings of the National Academy of Sciences of the United States of America 2007 104 3 973 978
27. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C., De Maria R., Identification and expansion of the tumorigenic lung cancer stem cell population Cell Death and Differentiation 2008 15 3 504 514
28. Ma S., Chan K. W., Guan X.-Y., In search of liver cancer stem cells Stem Cell Reviews 2008 4 3 179 192
29. Schatton T., Murphy G. F., Frank N. Y., Yamaura K., Waaga-Gasser A. M., Gasser M., Zhan Q., Jordan S., Duncan L. M., Weishaupt C., Fuhlbrigge R. C., Kupper T. S., Sayegh M. H., Frank M. H., Identification of cells initiating human melanomas Nature 2008 451 7176 345 349
30. Li C., Lee C. J., Simeone D. M., Identification of human pancreatic cancer stem cells Methods in Molecular Biology 2009 568 161 173
31. Collins A. T., Berry P. A., Hyde C., Stower M. J., Maitland N. J., Prospective identification of tumorigenic prostate cancer stem cells Cancer Research 2005 65 23 10946 10951
32. Ailles L., Prince M., Cancer stem cells in head and neck squamous cell carcinoma Methods in Molecular Biology 2009 568 175 193
33. Winquist R. J., Boucher D. M., Wood M., Furey B. F., Targeting cancer stem cells for more effective therapies: taking out cancer's locomotive engine Biochemical Pharmacology 2009 78 4 326 334
34. Garcion E., Naveilhan P., Berger F., Wion D., Cancer stem cells: beyond Koch's postulates Cancer Letters 2009 278 1 3 8
35. Adams J. M., Strasser A., Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Research 2008 68 11 4018 4021
36. Blagosklonny M. V., Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance Cell Cycle 2005 4 12 1693 1698
37. Vlashi E., McBride W. H., Pajonk F., Radiation responses of cancer stem cells Journal of Cellular Biochemistry 2009 108 2 339 342
38. Guenechea G., Gan O. I., Dorrell C., Dick J. E., Distinct classes of human stem cells that differ in proliferative and self-renewal potential Nature Immunology 2001 2 1 75 82
39. Hope K. J., Jin L., Dick J. E., Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity Nature Immunology 2004 5 7 738 743
40. Jordan C. T., Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 2009 4 3 203 205
41. Lorusso G., Regg C., The tumor microenvironment and its contribution to tumor evolution toward metastasis Histochemistry and Cell Biology 2008 130 6 1091 1103
42. Woodward W. A., Chen M. S., Behbod F., Alfaro M. P., Buchholz T. A., Rosen J. M., WNT/ -catenin mediates radiation resistance of mouse mammary progenitor cells Proceedings of the National Academy of Sciences of the United States of America 2007 104 2 618 623
43. Chiou S.-H., Kao C.-L., Chen Y.-W., Chien C.-S., Hung S.-C., Lo J.-F., Chen Y.-J., Ku H.-H., Hsu M.-T., Wong T.-T., Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor PLoS One 2008 3 5
44. Diehn M., Cho R. W., Lobo N. A., Kalisky T., Dorie M. J., Kulp A. N., Qian D., Lam J. S., Ailles L. E., Wong M., Joshua B., Kaplan M. J., Wapnir I., Dirbas F. M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S. K., Quake S. R., Brown J. M., Weissman I. L., Clarke M. F., Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 2009 458 7239 780 783
45. Blazek E. R., Foutch J. L., Maki G., Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia International Journal of Radiation Oncology Biology Physics 2007 67 1 1 5
46. Zhou G.-B., Zhang J., Wang Z.-Y., Chen S.-J., Chen Z., Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy Philosophical Transactions of the Royal Society of London 2007 362 1482 959 971
47. Petrie K., Zelent A., Waxman S., Differentiation therapy of acute myeloid leukemia: past, present and future Current Opinion in Hematology 2009 16 2 84 91
48. Yagui-Beltrn A., He B., Jablons D. M., The role of cancer stem cells in neoplasia of the lung: past, present and future Clinical Translational Oncology 2008 10 11 719 725
49. O'Brien C. A., Pollett A., Gallinger S., Dick J. E., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice Nature 2007 445 7123 106 110
50. Dalerba P., Dylla S. J., Park I.-K., Liu R., Wang X., Cho R. W., Hoey T., Gurney A., Huang E. H., Simeone D. M., Shelton A. A., Parmiani G., Castelli C., Clarke M. F., Phenotypic characterization of human colorectal cancer stem cells Proceedings of the National Academy of Sciences of the United States of America 2007 104 24 10158 10163
51. Neuzil J., Stantic M., Zobalova R., Chladova J., Wang X., Prochazka L., Dong L., Andera L., Ralph S. J., Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochemical and Biophysical Research Communications 2007 355 4 855 859
52. Matsumoto K., Arao T., Tanaka K., Kaneda H., Kudo K., Fujita Y., Tamura D., Aomatsu K., Tamura T., Yamada Y., Saijo N., Nishio K., mTOR signal and hypoxia-inducible factor-1 regulate CD133 expression in cancer cells Cancer Research 2009 69 18 7160 7164
53. Benitah S. A., Frye M., Glogauer M., Watt F. M., Stem cell depletion through epidermal deletion of Rac1 Science 2005 309 5736 933 935
54. Blair A., Hogge D. E., Ailles L. E., Lansdorp P. M., Sutherland H. J., Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo Blood 1997 89 9 3104 3112
55. Passegu E., Jamieson C. H. M., Ailles L. E., Weissman I. L., Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proceedings of the National Academy of Sciences of the United States of America 2003 100 supplement 1 11842 11849
56. Kondo T., Setoguchi T., Taga T., Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line Proceedings of the National Academy of Sciences of the United States of America 2004 101 3 781 786
57. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D. G., Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic Cancer Research 2005 65 14 6207 6219
58. Stevenson M., Mostertz W., Acharya C., Kim W., Walters K., Barry W., Higgins K., Tuchman S. A., Crawford J., Vlahovic G., Ready N., Onaitis M., Potti A., Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma Clinical Cancer Research 2009 15 24 7553 7561
59. Seo D.-C., Sung J.-M., Cho H.-J., Yi H., Seo K.-H., Choi I.-S., Kim D.-K., Kim J.-S., Abd El-Aty A. M., Shin H.-C., Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells Molecular Cancer 2007 6
60. Glinsky G. V., "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management Journal of Clinical Oncology 2008 26 17 2846 2853
61. Frosina G., DNA repair in normal and cancer stem cells, with special reference to the central nervous system Current Medicinal Chemistry 2009 16 7 854 866
62. Dean M., Fojo T., Bates S., Tumour stem cells and drug resistance Nature Reviews Cancer 2005 5 4 275 284
63. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I. R., Lu L., Irvin D., Black K. L., Yu J. S., Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Molecular Cancer 2006 5
64. Trumpp A., Wiestler O. D., Mechanisms of disease: cancer stem cells-targeting the evil twin Nature Clinical Practice Oncology 2008 5 6 337 347
65. Bao S., Wu Q., McLendon R. E., Hao Y., Shi Q., Hjelmeland A. B., Dewhirst M. W., Bigner D. D., Rich J. N., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 2006 444 7120 756 760
66. Hambardzumyan D., Squatrito M., Holland E. C., Radiation resistance and stem-like cells in brain tumors Cancer Cell 2006 10 454 456
67. Blasco M. A., Telomeres and human disease: ageing, cancer and beyond Nature Reviews Genetics 2005 6 8 611 622
68. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., Kantarjian H., Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia Blood 2006 107 9 3469 3473
69. Miller W. H. Jr., Schipper H. M., Lee J. S., Singer J., Waxman S., Mechanisms of action of arsenic trioxide Cancer Research 2002 62 14 3893 3903
70. Dikmen Z. G., Gellert G. C., Jackson S., Gryaznov S., Tressler R., Dogan P., Wright W. E., Shay J. W., In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor Cancer Research 2005 65 17 7866 7873
71. Vonderheide R. H., Domchek S. M., Schultze J. L., George D. J., Hoar K. M., Chen D.-Y., Stephans K. F., Masutomi K., Loda M., Xia Z., Anderson K. S., Hahn W. C., Nadler L. M., Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes Clinical Cancer Research 2004 10 3 828 839
72. Danet-Desnoyers G.-A. H., Luongo J. L., Bonnet D. A., Domchek S. M., Vonderheide R. H., Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients Experimental Hematology 2005 33 11 1275 1280
73. Dean M., ABC transporters, drug resistance, and cancer stem cells Journal of Mammary Gland Biology and Neoplasia 2009 14 1 3 9
74. Gatti L., Beretta G. L., Cossa G., Zunino F., Perego P., ABC transporters as potential targets for modulation of drug resistance Mini-Reviews in Medicinal Chemistry 2009 9 9 1102 1112
75. Hambardzumyan D., Becher O. J., Rosenblum M. K., Pandolfi P. P., Manova-Todorova K., Holland E. C., PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo Genes and Development 2008 22 4 436 448
76. Rao G., Pedone C. A., Valle L. D., Reiss K., Holland E. C., Fults D. W., Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice Oncogene 2004 23 36 6156 6162
77. Ma S., Lee T. K., Zheng B.-J., Chan K. W., Guan X.-Y., CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway Oncogene 2008 27 12 1749 1758
78. Hambardzumyan D., Becher O. J., Holland E. C., Cancer stem cells and survival pathways Cell Cycle 2008 7 10 1371 1378
79. Chumsri S., Matsui W., Burger A. M., Therapeutic implications of leukemic stem cell pathways Clinical Cancer Research 2007 13 22 6549 6554
80. Levis M., Murphy K. M., Pham R., Kim K.-T., Stine A., Li L., McNiece I., Smith B. D., Small D., Internal tandem duplications of the FLT3 gene are present in leukemia stem cells Blood 2005 106 2 673 680
81. Knapper S., Burnett A. K., Littlewood T., Kell W. J., Agrawal S., Chopra R., Clark R., Levis M. J., Small D., A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood 2006 108 10 3262 3270
82. Saelens X., Festjens N., Vande Walle L., Van Gurp M., Van Loo G., Vandenabeele P., Toxic proteins released from mitochondria in cell death Oncogene 2004 23 16 2861 2874
83. LaCasse E. C., Mahoney D. J., Cheung H. H., Plenchette S., Baird S., Korneluk R. G., IAP-targeted therapies for cancer Oncogene 2008 27 48 6252 6275
84. Vellanki S. H. K., Grabrucker A., Liebau S., Proepper C., Eramo A., Braun V., Boeckers T., Debatin K.-M., Fulda S., Small-molecule XIAP inhibitors enhance -irradiation-induced apoptosis in glioblastoma Neoplasia 2009 11 8 743 752
85. Sarkar F. H., Li Y., Wang Z., Kong D., NF- B signaling pathway and its therapeutic implications in human diseases International Reviews of Immunology 2008 27 5 293 319
86. Guzman M. L., Neering S. J., Upchurch D., Grimes B., Howard D. S., Rizzieri D. A., Luger S. M., Jordan C. T., Nuclear factor- B is constitutively activated in primitive human acute myelogenous leukemia cells Blood 2001 98 8 2301 2307
87. Kordes U., Krappmann D., Heissmeyer V., Ludwig W. D., Scheidereit C., Transcription factor NF- B is constitutively activated in acute lymphoblastic leukemia cells Leukemia 2000 14 3 399 402
88. Wang W., Abbruzzese J. L., Evans D. B., Larry L., Cleary K. R., Chiao P. J., The nuclear factor- B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells Clinical Cancer Research 1999 5 1 119 127
89. Shattuck-Brandt R. L., Richmond A., Enhanced degradation of I- B contributes to endogenous activation of NF- B in Hs294T melanoma cells Cancer Research 1997 57 14 3032 3039
90. Calabrese C., Poppleton H., Kocak M., Hogg T. L., Fuller C., Hamner B., Oh E. Y., Gaber M. W., Finklestein D., Allen M., Frank A., Bayazitov I. T., Zakharenko S. S., Gajjar A., Davidoff A., Gilbertson R. J., A perivascular niche for brain tumor stem cells Cancer Cell 2007 11 1 69 82
91. Vermeulen L., De Sousa E Melo F., Van Der Heijden M., Cameron K., De Jong J. H., Borovski T., Tuynman J. B., Todaro M., Merz C., Rodermond H., Sprick M. R., Kemper K., Richel D. J., Stassi G., Medema J. P., Wnt activity defines colon cancer stem cells and is regulated by the microenvironment Nature Cell Biology 2010 12 5 468 476
92. Korkaya H., Wicha M. S., Cancer stem cells: nature versus nurture Nature Cell Biology 2010 12 5 419 421
93. Huff C. A., Matsui W., Smith B. D., Jones R. J., The paradox of response and survival in cancer therapeutics Blood 2006 107 2 431 434
94. Sung P. H., Wen J., Bang S., Park S., Song S. Y., CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells International Journal of Cancer 2009 125 10 2323 2331
95. Becker J. C., Ugurel S., Schrama D., Strategies to optimize the use of targeted agents for tumor therapy Journal of the German Society of Dermatology 2008 6 4 281 286
96. Bernier J., Current state-of-the-art for concurrent chemoradiation Seminars in Radiation Oncology 2009 19 1 3 10
97. Newman E. A., Simeone D. M., Mulholland M. W., Adjuvant treatment strategies for pancreatic cancer Journal of Gastrointestinal Surgery 2006 10 6 916 926
98. Liu J.-M., Mao B.-Y., Hong S., Liu Y.-H., Wang X.-J., The postoperative brain tumour stem cell (BTSC) niche and cancer recurrence Advances in Therapy 2008 25 5 389 398
99. Barker N., Clevers H., Mining the Wnt pathway for cancer therapeutics Nature Reviews Drug Discovery 2006 5 12 997 1014
100. Weerkamp F., van Dongen J. J. M., Staal F. J. T., Notch and Wnt signaling in T-lymphocyte development and acute lymphoblastic leukemia Leukemia 2006 20 7 1197 1205
101. Lu D., Zhao Y., Tawatao R., Cottam H. B., Sen M., Leoni L. M., Kipps T. J., Corr M., Carson D. A., Activation of the Wnt signaling pathway in chronic lymphocytic leukemia Proceedings of the National Academy of Sciences of the United States of America 2004 101 9 3118 3123
102. Staal F. J. T., Clevers H. C., WNT signalling and haematopoiesis: a WNT-WNT situation Nature Reviews Immunology 2005 5 1 21 30
103. Hadjihannas M. V., Brckner M., Jerchow B., Birchmeier W., Dietmaier W., Behrens J., Aberrant Wnt/ -catenin signaling can induce chromosomal instability in colon cancer Proceedings of the National Academy of Sciences of the United States of America 2006 103 28 10747 10752
104. Shiras A., Chettiar T S., Shepal V., Rajendran G., Prasad G. R., Shastry P., Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma Stem Cells 2007 25 6 1478 1489
105. Pang R. W. C., Poon R. T. P., From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now Oncology 2007 72 supplement 1 30 44
106. Artavanis-Tsakonas S., Rand M. D., Lake R. J., Notch signaling: cell fate control and signal integration in development Science 1999 284 5415 770 776
107. Lehar S. M., Dooley J., Farr A. G., Bevan M. J., Notch ligands delta1 and jagged1 transmit distinct signals to T-cell precursors Blood 2005 105 4 1440 1447
108. Phillips T. M., McBride W. H., Pajonk F., The response of CD24-/low/CD44+ breast cancer-initiating cells to radiation Journal of the National Cancer Institute 2006 98 24 1777 1785
109. Scharpfenecker M., Kruse J. J. C. M., Sprong D., Russell N. S., ten Dijke P., Stewart F. A., Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells International Journal of Radiation Oncology Biology Physics 2009 73 2 506 513
110. Fan X., Matsui W., Khaki L., Stearns D., Chun J., Li Y.-M., Eberhart C. G., Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors Cancer Research 2006 66 15 7445 7452
111. Bols V., Blanco M., Medina V., Aparicio G., Daz-Prado S., Grande E., Notch signalling in cancer stem cells Clinical and Translational Oncology 2009 11 1 11 19
112. Sun P., Xia S., Lal B., Eberhart C. G., Quinones-Hinojosa A., Maciaczyk J., Matsui W., DiMeco F., Piccirillo S. M., Vescovi A. L., Laterra J., DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation Stem Cells 2009 27 7 1473 1486
113. Medina V., Calvo M. B., Daz-Prado S., Espada J., Hedgehog signalling as a target in cancer stem cells Clinical and Translational Oncology 2009 11 4 199 207
114. Lauth M., Toftgrd R., The Hedgehog pathway as a drug target in cancer therapy Current Opinion in Investigational Drugs 2007 8 6 457 461
115. Borzillo G. V., Lippa B., The Hedgehog signaling pathway as a target for anticancer drug discovery Current Topics in Medicinal Chemistry 2005 5 2 147 157
116. Jiang J., Hui C.-C., Hedgehog signaling in development and cancer Developmental Cell 2008 15 6 801 812
117. Scales S. J., de Sauvage F. J., Mechanisms of Hedgehog pathway activation in cancer and implications for therapy Trends in Pharmacological Sciences 2009 30 6 303 312
118. Jenkins D., Hedgehog signalling: emerging evidence for non-canonical pathways Cellular Signalling 2009 21 7 1023 1034
119. Berman D. M., Karhadkar S. S., Hallahan A. R., Pritchard J. I., Eberhart C. G., Watkins D. N., Chen J. K., Cooper M. K., Taipale J., Olson J. M., Beachy P. A., Medulloblastoma growth inhibition by Hedgehog pathway blockade Science 2002 297 5586 1559 1561
120. Singh S. K., Hawkins C., Clarke I. D., Squire J. A., Bayani J., Hide T., Henkelman R. M., Cusimano M. D., Dirks P. B., Identification of human brain tumour initiating cells Nature 2004 432 7015 396 401
121. Wang C. H., Chiou S. H., Chou C. P., Chen Y. C., Huang Y. J., Peng C. A., Photothermolysis of glioblastoma stemlike cells targeting by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine: Nanotechnology, Biology and Medicine. In press